{"id":5079,"date":"2023-09-20T17:32:31","date_gmt":"2023-09-20T12:02:31","guid":{"rendered":"https:\/\/lakshmishree.com\/blog\/?p=5079"},"modified":"2023-09-23T10:01:37","modified_gmt":"2023-09-23T04:31:37","slug":"valiant-laboratories-ipo","status":"publish","type":"post","link":"https:\/\/lakshmishree.com\/blog\/valiant-laboratories-ipo\/","title":{"rendered":"Valiant Laboratories IPO Details - Complete Overview of Valiant Laboratories Limited IPO"},"content":{"rendered":"\n

Valiant Laboratories IPO Price: <\/strong>\u20b9133 to \u20b9140 per share
IPO Date Range:<\/strong> Sep 27, 2023 - Oct 3, 2023<\/p>\n\n\n\n

\n
\n
\"Valiant<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Core Foundation:<\/h2>\n\n\n\n

Valiant Laboratories Limited, a pharmaceutical ingredient manufacturing entity, was established in 1980. With its primary focus on producing Paracetamol, the company has positioned itself as a significant player in the pharmaceutical sector.<\/p>\n<\/div>\n<\/div>\n\n\n\n

Business Essence:<\/h2>\n\n\n\n

The company's core strength lies in its manufacturing capabilities. Situated in Palghar, Maharashtra, its manufacturing unit spans 2,000 sq. mts. of land. With an impressive annual installed capacity of 9,000 MT, Valiant Laboratories is equipped to meet the market's demands. Additionally, the company has invested in an R&D Facility, which is well-equipped with an analytical laboratory and infrastructure, facilitating developmental activities in existing products.<\/p>\n\n\n\n

Financial Highlights:<\/strong><\/h2>\n\n\n\n

For the fiscal years 2023, 2022, and 2021, the company reported operating revenues amounting to Rs. 3,339.10 million, Rs. 2,915.23 million, and Rs. 1,823.69 million, respectively.<\/p>\n\n\n\n

Raw Material Insights:<\/strong><\/h2>\n\n\n\n

Valiant Laboratories sources its primary raw material, Para Amino Phenol, essential for manufacturing Paracetamol, from countries like China and Cambodia.<\/p>\n\n\n\n

Team and Workforce:<\/strong><\/h2>\n\n\n\n

As of April 30, 2023, the company takes pride in its dedicated team of 86 employees contributing to its success.<\/p>\n\n\n\n

Bidding Starts In<\/h2>\n\n\n\n
-<\/div>
DAYS<\/div><\/div>
-<\/div>
HOURS<\/div><\/div>
-<\/div>
MINUTES<\/div><\/div>
-<\/div>
SECONDS<\/div><\/div><\/div>\n\n\n\n
APPLY NOW<\/span><\/path><\/svg>

Dream Big, Start with an IPO. Choose Lakshmishree.<\/p><\/a><\/div>\n\n\n\n

Valiant Laboratories IPO Specifics:<\/h2>\n\n\n\n
IPO Date<\/td>September 27, 2023 to October 3, 2023<\/td><\/tr>
Listing Date<\/td>Monday, October 9, 2023<\/td><\/tr>
Face Value<\/td>\u20b910 per share<\/td><\/tr>
Price Band<\/td>\u20b9133 to \u20b9140 per share<\/td><\/tr>
Lot Size<\/td>105 Shares<\/td><\/tr>
Total Issue Size<\/td>10,890,000 shares
(aggregating up to \u20b9152.46 Cr)<\/td><\/tr>
Fresh Issue<\/td>10,890,000 shares
(aggregating up to \u20b9152.46 Cr)<\/td><\/tr>
Issue Type<\/td>Book Built Issue IPO<\/td><\/tr>
Listing At<\/td>BSE, NSE<\/td><\/tr>
Share holding pre issue<\/td>32,560,000<\/td><\/tr>
Share holding post issue<\/td>43,450,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Valiant Laboratories IPO Lot Size<\/h2>\n\n\n\n

The minimum lot size to apply in this Valiant Laboratories Limited IPO consists of 105 shares, requiring an investment of \u20b914,700.<\/p>\n\n\n\n

Application<\/th>Lots<\/th>Shares<\/th>Amount<\/th><\/tr><\/thead>
Retail (Min)<\/td>1<\/td>105<\/td>\u20b914,700<\/td><\/tr>
Retail (Max)<\/td>13<\/td>1365<\/td>\u20b9191,100<\/td><\/tr>
S-HNI (Min)<\/td>14<\/td>1,470<\/td>\u20b9205,800<\/td><\/tr>
S-HNI (Max)<\/td>68<\/td>7,140<\/td>\u20b9999,600<\/td><\/tr>
B-HNI (Min)<\/td>69<\/td>7,245<\/td>\u20b91,014,300<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Valiant Laboratories IPO Reservation<\/h2>\n\n\n\n
QIB Shares Offered<\/td>Not more than 50.00% of the Net offer<\/td><\/tr>
NII (HNI) Shares Offered<\/td>Not less than 15.00% of the Offer<\/td><\/tr>
Retail Shares Offered<\/td>Not less than 35.00% of the Offer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Valiant Laboratories IPO Timetable (Important Dates)<\/h2>\n\n\n\n
IPO Open Date<\/td>Wednesday, September 27, 2023<\/td><\/tr>
IPO Close Date<\/td>Tuesday, October 3, 2023<\/td><\/tr>
Basis of Allotment<\/td>Friday, October 6, 2023<\/td><\/tr>
Initiation of Refunds<\/td>Monday, October 9, 2023<\/td><\/tr>
Credit of Shares to Demat<\/td>Tuesday, October 10, 2023<\/td><\/tr>
Listing Date<\/td>Wednesday, October 11, 2023<\/td><\/tr>
Cut-off time for UPI mandate confirmation<\/td>5 PM on October 3, 2023<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Don't Miss Out!<\/h2>
<\/div>

Whether you're a seasoned investor or just starting out, Lakshmishree ensures you don't miss out on premier IPO opportunities. Dive into the future of investing with Lakshmishree.<\/p><\/div>\n\n\n\n

\n
APPLY NOW<\/a><\/div>\n<\/div>\n\n\n\n

Valiant Laboratories Limited IPO Financial Information<\/h2>\n\n\n\n

As of March 31, 2023, the company's assets stood at \u20b9212.76 crores, with a revenue of \u20b9338.77 crores. The profit after tax for the same period was \u20b929.00 crores. Here, you can get the complete data of the past three years:<\/p>\n\n\n\n

Period Ended<\/th>31 Mar 2021<\/th>31 Mar 2022<\/th>31 Mar 2023<\/th><\/tr><\/thead>
Assets<\/td>106.31<\/td>181.81<\/td>212.76<\/td><\/tr>
Revenue<\/td>183.78<\/td>293.47<\/td>338.77<\/td><\/tr>
Profit After Tax<\/td>30.59<\/td>27.50<\/td>29.00<\/td><\/tr>
Net Worth<\/td>88.58<\/td>71.46<\/td>100.49<\/td><\/tr>
Reserves and Surplus<\/td><\/td><\/td><\/td><\/tr>
Total Borrowing<\/td>0.35<\/td>60.68<\/td>59.40<\/td><\/tr><\/tbody><\/table>
Amount in \u20b9 Crore<\/small><\/figcaption><\/figure>\n\n\n\n

Key Performance Indicator - Valiant Laboratories IPO<\/h2>\n\n\n\n

The market capitalization of Valiant Laboratories Limited IPO stands at Rs 608.3 Crore, with a P\/E ratio of 15.71.<\/p>\n\n\n\n

KPI<\/th>Values<\/th><\/tr><\/thead>
P\/E (x)<\/td>15.71<\/td><\/tr>
Market Cap (\u20b9 Cr.)<\/td>608.3<\/td><\/tr>
ROE<\/td>33.73%<\/td><\/tr>
ROCE<\/td>22.76%<\/td><\/tr>
Debt\/Equity<\/td>0.59<\/td><\/tr>
EPS (Rs)<\/td>8.91<\/td><\/tr>
RoNW<\/td>28.86%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Objects of the Issue:<\/strong><\/h2>\n\n\n\n

Valiant Laboratories aims to channel the net proceeds from the IPO towards:<\/p>\n\n\n\n